A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status

Autor: Talieh Kazerooni, Mina Azmoon, Vivian Frank, Ernst Hienrich Schmidt, Mohammad Ebrahim Parsanezhad, Afsun Zarei, Abdoreza Rajaeefard, Saeed Alborzi
Rok vydání: 2010
Předmět:
Time Factors
Iran
law.invention
Gonadotropin-Releasing Hormone
Hospitals
University
Follicle-stimulating hormone
0302 clinical medicine
Randomized controlled trial
law
Germany
Testosterone
Prospective Studies
Triptorelin Pamoate
030219 obstetrics & reproductive medicine
Estradiol
Leiomyoma
Aromatase Inhibitors
Letrozole
Obstetrics and Gynecology
Triptorelin
Tumor Burden
3. Good health
Treatment Outcome
030220 oncology & carcinogenesis
Uterine Neoplasms
Female
Follicle Stimulating Hormone
Human
Gonadotropin
medicine.drug
Adult
medicine.medical_specialty
Antineoplastic Agents
Hormonal
medicine.drug_class
03 medical and health sciences
Gonadotropin-releasing hormone agonist
Nitriles
medicine
Humans
Gynecology
Aromatase inhibitor
business.industry
Myoma
Luteinizing Hormone
Triazoles
medicine.disease
Hormones
Reproductive Medicine
Hot Flashes
business
Zdroj: Fertility and Sterility. 93:192-198
ISSN: 0015-0282
DOI: 10.1016/j.fertnstert.2008.09.064
Popis: Objective To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas. Design Multicenter, randomized, controlled clinical trial. Setting University hospitals. Patient(s) A total of 70 subjects with a single uterine myoma measuring ≥5 cm. Subjects were randomized into two groups with use of a random table. They were treated with aromatase inhibitor (group A) or GnRHa (group B). Intervention(s) Group A received letrozole (2.5 mg/d) for 12 weeks. Group B received triptorelin (3.75 mg/mo) for 12 weeks. Main Outcome Measure(s) Measurement of myoma volume and E 2 , FSH, LH, and T levels. Result(s) Total myoma volume decreased by 45.6% in group A and 33.2% in group B. Reductions in myoma volume in the two groups were statistically significant. There was no significant change in hormonal milieu in group A. The serum level of hormones significantly decreased in group B by the 12th week of treatment. Conclusion(s) Uterine myoma volume was successfully reduced by use of an aromatase inhibitor. Rapid onset of action and avoidance of initial gonadotropin flare with an aromatase inhibitor may be advantageous for short-term management of women with myomas of any size who are to be managed transiently and who wish to avoid surgical intervention, specifically women with unexplained infertility having uterine myoma.
Databáze: OpenAIRE
Externí odkaz: